The 5th China International Import Expo (CIIE) witnessed the establishment of the MET HER2 precision diagnosis alliance, a collaborative initiative involving AstraZeneca, Daiichi Sankyo, HutchMed, Roche Diagnostics, AmoyDx, LBP Medicine, Deep Informatics, Histo Medical Pathological Diagnosis Center, Rightongene Bio, and Genetron. This alliance aims to enhance the implementation of HER2 targeting novel diagnosis plans in China.
Daiichi Sankyo’s Commitment
Daiichi Sankyo, an important member of the alliance based in Japan, has pledged to boost the implementation of HER2 targeting novel diagnosis plans in China alongside other members. This commitment underscores the alliance’s focus on improving clinical outcomes for patients with HER2-mutated non-small cell lung cancer (NSCLC).
HER2 Mutation and Clinical Need
HER2 mutation, one of the driving genes associated with non-small cell lung cancer (NSCLC), is closely related to a poor prognosis in patients. This makes the development of effective clinical treatments an urgent need. The alliance aims to address this challenge by advancing innovative diagnostic solutions.
Enhertu’s Regulatory Progress
Daiichi/AstraZeneca’s HER2-targeted antibody drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) was fast-tracked to approval in the US in August this year for the treatment of adult patients with unresectable or metastatic HER2-mutated NSCLC previously treated with systemic therapy. The drug is currently under regulatory review in China, highlighting the alliance’s potential impact on the global treatment landscape for HER2-mutated cancers.-Fineline Info & Tech
